Literature DB >> 10265845

Total formulary review--the easy way.

K Chase, J D Meyer, W N Kelly.   

Abstract

In an effort to minimize drug costs, many hospital pharmacy services have limited their drug inventories through the development of a formulary. Evaluation of drug products for addition to the formulary is the responsibility of the Pharmacy and Therapeutics (P & T) Committee. The deletion of rarely used or outdated products is often overlooked. As a means to "clean up" the formulary, Hamot Medical Center (HMC) underwent a total formulary review. Drugs were separated into classes as defined by the American Hospital Formulary Service (AHFS). Approximately three drug classes were evaluated each month by the P & C Committee. Evaluation criteria was based on the following factors: current formulary status, usage statistics, negative comments appearing in six current publications, hospital acquisition cost, and number of formularies containing each product. A final compilation of all deletions and additions were distributed to all medical staff department and division chiefs. Following receipt of all their comments, a final draft of the formulary was made and prepared for publication. This system is a simple, uncomplicated means of either revising or beginning a formulary. It evaluates a drug based on efficacy, individual hospital usage, and cost of the drug while allowing for input of the medical staff. The end result is a formulary tailored to best fit each institution.

Mesh:

Year:  1984        PMID: 10265845

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  3 in total

1.  Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

Authors:  R J Lipsy
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

2.  An Annual Formulary Review Strategy Implemented by a Saudi Health System.

Authors:  Laila Carolina Abu Esba
Journal:  P T       Date:  2016-08

3.  Off-Label Medication Use in the Inpatient Palliative Care Unit.

Authors:  Jung Hye Kwon; Min Ji Kim; Sebastian Bruera; Minjeong Park; Eduardo Bruera; David Hui
Journal:  J Pain Symptom Manage       Date:  2017-05-04       Impact factor: 3.612

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.